Alvotech (ALVO)
- Previous Close
13.50 - Open
13.46 - Bid 13.47 x 200
- Ask 13.52 x 200
- Day's Range
13.30 - 13.52 - 52 Week Range
6.70 - 18.00 - Volume
38,756 - Avg. Volume
237,066 - Market Cap (intraday)
3.774B - Beta (5Y Monthly) -0.02
- PE Ratio (TTM)
-- - EPS (TTM)
-2.43 - Earnings Date May 21, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.50
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
www.alvotech.com999
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ALVO
Performance Overview: ALVO
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALVO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALVO
Valuation Measures
Market Cap
3.77B
Enterprise Value
4.84B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
39.40
Price/Book (mrq)
--
Enterprise Value/Revenue
52.92
Enterprise Value/EBITDA
-8.78
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.45%
Return on Equity (ttm)
--
Revenue (ttm)
93.38M
Net Income Avi to Common (ttm)
-551.73M
Diluted EPS (ttm)
-2.43
Balance Sheet and Cash Flow
Total Cash (mrq)
11.16M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-243.73M
Research Analysis: ALVO
Company Insights: ALVO
ALVO does not have Company Insights